MDL No.: MFCD03455075
Storage: -20C
UNSPSC Code: 12352203
Features and Benefits: Antibody BioguaranteeEvaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
General description: Guanylyl cyclase (GC) catalyzes the conversion of guanosine-5'-triphosphate (GTP) to cyclic guanosine-3',5-monophosphate (cGMP) and pyrophosphate. This reaction requires Mg2+ or Mn2+. The enzyme consists of α and β subunits of ~80kDa and ~70kDa respectively. Both the units are required for catalytic activity. The N-terminal domains of the subunits are essential for the stimulation of the enzyme by NO. Dimerization is mediated by the central portion of GC. The C-terminus domain of both subunits forms the catalytic domain.
Application: Anti-Guanylyl Cyclase α1 antibody produced in rabbit is suitable for immunohistochemistry at a working dilution of 1:100 using trypsin-treated human, bovine and mouse heart tissue and immunoprecipitation at 5-10μg concentration using 60-120μg of a cytosolic fraction of rat brain. It is also suitable for western blot analysis using cytosolic fraction of rat brain at a working dilution of 1:10,000.It was used as a primary antibody for immunohistochemical:. localization of α1 subunits of sGC (soluble guanylate cyclase) in the guinea pig gastrointestinal tract . detection of expression of sGC in the vasculature of rat skeletal muscle . localization of the functional subunit of NO receptors, sGCα1 in guinea pig caecum
Biochem/physiol Actions: The enzyme (GC) is a major physiological receptor for nitric oxide (NO), an important intra- and intercellular membrane-permeant signaling molecule. Gaseous NO binds to Fe2+ in the prosthetic heme group of the enzyme. NO binding is followed by disruption of the β1 subunit histidine105 bond to iron and activation of the enzyme. GC forms a complex with NO and cGMP and regulates smooth muscle relaxation, inflammation, platelet adhesion and aggregation, pulmonary physiology and neuronal function. It is an important target for NO-releasing and non-NO-releasing activator drugs in human cardiovascular therapy.
Immunogen: synthetic peptide corresponding to amino acid residues 673-690 of rat soluble Guanylyl cyclase alpha1, conjugated to KLH with glutaraldehyde. The corresponding human sequence differs by 2 amino acids.
Physical form: Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide
RIDADR: NONH for all modes of transport
WGK Germany: 3